Component information
No US or EU label exists for this exact combination, so information is shown for each component.
- Acyclovir listed as aciclovir
Use: Acyclovir tablets are indicated for the treatment of initial episodes and the management of recurrent episodes of genital herpes. US FDA label
Kidney dosing: Acyclovir (single-agent)Show full dosing details
- CrCl ≥60 mL/min/1.73 m2
- Oral: usual dosing. IV: usual dose every 8 hours (label: CrCl >50).
- CrCl 30–59 mL/min/1.73 m2
- Oral: no change for 200 mg or 400 mg regimens (CrCl >10) or 800 mg five times daily (CrCl >25) (label). IV: CrCl >50, every 8 hours; CrCl 25–50, 100% of the dose every 12 hours (label).
- CrCl 15–29 mL/min/1.73 m2
- Oral: 800 mg every 4 hours regimen: CrCl 10–25, 800 mg every 8 hours; 200 mg and 400 mg regimens unchanged (CrCl >10) (label). IV: CrCl 25–29, every 12 hours; CrCl 10–25, 100% of the dose every 24 hours (label).
- CrCl <15 mL/min/1.73 m2 (not on dialysis)
- Oral: CrCl 10–25, 800 mg every 8 hours; CrCl 0–10, 200 mg every 12 hours (200 mg and 400 mg regimens) or 800 mg every 12 hours (800 mg regimen). IV: CrCl 10–25, 100% of the dose every 24 hours; CrCl 0–10, 50% of the dose every 24 hours (label). Neurotoxicity can occur even at adjusted doses.
- Hemodialysis (intermittent)
- Oral: use the CrCl 0–10 regimen (200 mg every 12 hours for the 200 mg and 400 mg regimens; 800 mg every 12 hours for the 800 mg regimen). IV: 50% of the dose every 24 hours (CrCl 0–10). Schedule a dose right after each dialysis; a 6-hour session lowers levels by about 60% (label). Watch for neurotoxicity (confusion, hallucinations, seizures), which can occur even at adjusted doses.
- Peritoneal dialysis
- No supplemental dose needed after adjusting the interval (oral and IV labels).
- CRRT
- Not in the labels. Published CRRT regimen (IV): 5 to 7.5 mg/kg every 24 hours; therapeutic drug monitoring where available (Li 2020).
- Dialyzable? Yes: half-life about 5 hours during hemodialysis (label).
- Monitoring Kidney function and hydration. Neurotoxicity (confusion, hallucinations, dysarthria, seizures) is most common in end-stage kidney disease (ESKD) and older adults, including at adjusted doses; stop the drug and consider hemodialysis if it occurs.
From the Acyclovir monograph (renalcarematters.com, reviewed).
Use: helps prevent sunburn US FDA label
Note: Fixed-dose combinations may not allow the dose changes advised for each component; check the strength and use the single agents if a component needs adjusting.
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney dosing for each component (single-agent) is shown under Component information.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosage forms
Philippines
- Per g topical ointment: 50 mg/100 mg
Registered products in the Philippines
1 product registered with the Food and Drug Administration (FDA) Philippines list Aciclovir + Zinc oxide as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
Hapivir ZOAciclovir + Zinc Oxide | 50 mg/100 mg per g Topical Ointment5 g Aluminum Collapsible Tube with White HDPE Screw Cap (Box of 1's) | Rx | Lloyd Laboratories Inc.Philippines | Trader: Folares Pharmaceuticals, Inc. | DR-XY35394 | Feb 3, 2029 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .